Entegrion Wins Award in 2009 New Product & Technology Awards Program

PR Log (Press Release) – Aug 26, 2009 – Research Triangle Park, N.C. – Entegrion, Inc., a privately owned life sciences product development company specializing in technologies for hemorrhage control, resuscitation, and tissue repair, was a winner in the 2009 New Product & Technology Awards. This national program, presented by the Mature Market Resource Center, a national clearinghouse for the senior market, is the first awards program of its kind to recognize the most innovative products and services for older adults and their families.

Entegrion’s Stasilon® hemostatic surgical pads and wound dressings received a Merit Award in the Safety Category. The Stasilon® technology provides hemorrhage control by rapidly activating the body’s hemostatic systems.  It is a textile system woven from a mixture of medical grade glass and bamboo rayon fibers specifically selected for their ability to rapidly activate platelets, agglutinate red cells, and constrict blood vessels. These interactions cause rapid clot formation within the wound bed, not in the textile pads and dressings themselves, resulting in uniquely non-adherent products that do not pull clot away to cause rebleeding or pain when removed from surgical or traumatic wounds.

“We were delighted to take part in the first annual New Product & Technology Awards program this year, and were honored to be selected as a winner,” says Stan Eskridge, chief executive officer of Entegrion.

Entries were judged by a distinguished panel of mature market experts from across the United States for overall excellence of design, content, creativity and relevance to the senior market.

About Entegrion
Entegrion is a life sciences company that selectively integrates synergistic technologies with those in its patent portfolio for development of novel devices and drugs for hemorrhage control, resuscitation, and advanced tissue repair. The company is based in North Carolina’s Research Triangle Park, and its portfolio includes platelet and plasma derived platform technologies that are being developed as infusible hemostatic agents for the control of internal hemorrhage and restoration of hemodynamic balance, topical gels and sprays for tissue repair and wound healing, and novel vehicles for targeted delivery of drugs to tumors as well as sites of inflammation and other vascular perturbation.  For more information, visit http://www.entegrion.com.